Table 2.

Clinical characteristics of patients with GCA.

	Patients with GCA (n = 25)
Age (year, mean ± SD)	68.8 ± 8.8
Male:Female	4:21 (16.0% : 84.0%)
Ethnicity
Caucasian	22 (88.0%)
African American	1 (4.0%)
Hispanic	0 (0%)
Asian	2 (8.0%)
Other	0 (0%)
Disease Duration (month, mean ± SD)	4.68 ± 4.43
Erythrocyte sedimentation rate (mean ± SD, mm/h)	33.72 ± 30.38
C-reactive protein (mean ± SD, mg/dL)	29.19 ± 50.97
Clinical symptoms
Headaches	12 (48.0%)
Eye involvement	7 (28.0%)
Claudication	8 (32.0%)
Polymyalgia rheumatica symptoms	9 (36.0%)
Constitutional symptoms	14 (56.0%)
Aortic/large vessel involvement	19 (76.0%)
Treatment of GCA
Untreated	12 (48.0%)
Prednisone	11 (44.0%)
dose (mg/day, mean ± SD)	25.1 ± 21.8 mg/day
Tocilizumab	4 (16.0%)

Values are n (%) unless otherwise noted.